Johnson & Johnson (NYSE:JNJ) Shares Purchased by Hardman Johnston Global Advisors LLC

Hardman Johnston Global Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 0.9% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 156,567 shares of the company’s stock after buying an additional 1,335 shares during the period. Hardman Johnston Global Advisors LLC’s holdings in Johnson & Johnson were worth $25,577,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Rice Partnership LLC raised its stake in shares of Johnson & Johnson by 12.3% during the third quarter. Rice Partnership LLC now owns 53,655 shares of the company’s stock worth $8,765,000 after purchasing an additional 5,868 shares during the last quarter. Aptus Capital Advisors LLC increased its stake in shares of Johnson & Johnson by 7.2% during the third quarter. Aptus Capital Advisors LLC now owns 77,500 shares of the company’s stock worth $12,661,000 after acquiring an additional 5,177 shares during the period. Fagan Associates Inc. raised its holdings in Johnson & Johnson by 0.3% during the third quarter. Fagan Associates Inc. now owns 46,282 shares of the company’s stock worth $7,561,000 after purchasing an additional 145 shares in the last quarter. Summit X LLC lifted its position in Johnson & Johnson by 7.8% in the third quarter. Summit X LLC now owns 3,486 shares of the company’s stock valued at $567,000 after purchasing an additional 252 shares during the period. Finally, Avantax Advisory Services Inc. boosted its holdings in Johnson & Johnson by 3.2% in the 3rd quarter. Avantax Advisory Services Inc. now owns 133,405 shares of the company’s stock valued at $21,793,000 after purchasing an additional 4,134 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. Bank of America reduced their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Credit Suisse Group started coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective for the company. Citigroup increased their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Finally, StockNews.com initiated coverage on Johnson & Johnson in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $181.75.

Insiders Place Their Bets

In related news, EVP Ashley Mcevoy sold 73,323 shares of the business’s stock in a transaction that occurred on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total value of $12,865,986.81. Following the completion of the sale, the executive vice president now directly owns 41,813 shares in the company, valued at $7,336,927.11. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Ashley Mcevoy sold 73,323 shares of the stock in a transaction on Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total value of $12,865,986.81. Following the transaction, the executive vice president now directly owns 41,813 shares of the company’s stock, valued at approximately $7,336,927.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 233,611 shares of company stock valued at $40,960,735. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $168.31 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The business has a fifty day moving average of $175.98 and a 200-day moving average of $171.06. The stock has a market cap of $440.04 billion, a price-to-earnings ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.23 by $0.12. The firm had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.13 EPS. As a group, analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.